MIRA shares surge 23.89% intraday after preclinical data shows Mira-55 has no THC-like CNS side effects.

MIRA Pharmaceuticals surged 23.89% intraday following the release of positive preclinical data for its drug candidate Mira-55, which demonstrated no central nervous system (CNS) side effects linked to cannabinoids or rimonabant in behavioral tests. The results, including no sedation, catalepsy, or motor impairment at tested doses, supported the company’s advancement toward an Investigational New Drug (IND) submission for inflammatory pain. The findings reinforced Mira-55’s differentiated pharmacological profile, showing morphine-comparable analgesia without opioid risks or psychoactive liabilities, a critical differentiator in the $45.3 billion non-opioid pain treatment market. The stock had previously declined 24% weekly and 39% year-to-date, but the robust preclinical outcomes, coupled with the absence of CNS adverse effects, reignited investor confidence in the pipeline’s potential.